GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.

Abstract

Nonalcoholic steatohepatitis (NASH), as a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. The pathogenesis of NASH is complex and multifactorial, obesity and type 2 diabetes mellitus (T2DM) have been implicated as major risk factors. Glucagon-like peptide-1 receptor (GLP-1R) is one of the most successful drug targets of T2DM and obesity, and its peptidic ligands have been proposed as potential therapeutic agents for NASH. In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

• Authors: Yan Chen, Ying-Na Xu, Chen-Yu Ye, Wen-Bo Feng, Qing-Tong Zhou, De-Hua Yang, Ming-Wei Wang
• Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin) Vol. 43 Issue 5 Pg. 1156-1166 (May 2022) ISSN: 1745-7254 [Electronic] United States
• PMID: 34934197 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to CPS and SIMM.

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Hypoglycemic Agents
• Glucagon-Like Peptide 1

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Glucagon-Like Peptide 1 (therapeutic use)
• Glucagon-Like Peptide-1 Receptor
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Non-alcoholic Fatty Liver Disease (drug therapy)
• Obesity (drug therapy)